Abstract

Selenium binding protein 1 (SELENBP1) has been known to be reduced in various types cancer, and epigenetic change is shown to be likely to account for the reduction of SELNEBP1 expression. With cDNA microarray comparative analysis, we found that SELENBP1 is markedly decreased in hepatitis B virus-X (HBx)-expressing cells. To clarify the effect of HBx on SELENBP1 expression, we compared the expression levels of SELENBP1 mRNA and protein by semi-quantitative RT-PCR, Northern blot, and Western blot. As expected, SELENBP1 expression was shown to be reduced in cells expressing HBx, and reporter gene analysis showed that the SELENBP1 promoter is repressed by HBx. In addition, the stepwise deletion of 5′ flanking promoter sequences resulted in a gradual decrease in basal promoter activity and inhibition of SELENBP1 expression by HBx. Moreover, immunohistochemistry on tissue microarrays containing 60 pairs of human liver tissue showed decreased intensity of SELENBP1 in tumor tissues as compared with their matched non-tumor liver tissues. Taken together, our findings suggest that inhibition of SELENBP1 expression by HBx might act as one of the causes in the development of hepatocellular carcinoma caused by HBV infection.

Highlights

  • Selenium (Se) has been recognized as an essential trace element exhibiting potent anti-carcinogenic properties

  • Several studies demonstrated that hepatitis B virus-X (HBx) is capable of transcriptional suppression

  • HBx has been shown to downregulate the expression of p53[38], XPB (p89, ERCC3) and XPD (p80, ERCC2) [51], 4

Read more

Summary

Introduction

Selenium (Se) has been recognized as an essential trace element exhibiting potent anti-carcinogenic properties. It has been suggested that SELENBP1 plays a role in regulating protein trafficking and secretion, as was it shown to regulate vesicular transport in an intra-golgi transport cell-free assay in vitro [3]. It has been shown that TGF-beta could regulate the expression of SELENBP1 in chronic allograft nephropathy [4]. SELENBP1 may be involved in anti-carcinogenic activities, such as growth regulation, reduction/oxidation modulation, and detoxification [5]. Reduced expressions of SELENBP1 with poor prognosis were shown in various carcinomas, including colorectal carcinoma [6,7], ovarian cancer [8], breast cancer [9,10], gastric carcinoma [11], lung adenocarcinoma [12,13,14], prostate cancer [15], thyroid carcinoma [16], bronchial epithelial cancer [17], esophageal adenocarcinoma [18], malignant melanoma [19], and hepatocellular carcinoma [20,21,22]. Its physiological role or the molecular mechanism in cancers are not clear at present

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call